Pluvicto

Narasimhan

Pharma

Novartis stands by $5B Pluvicto goal despite EU regulatory setback

Novartis CEO remains committed to Pluvicto and its radioligand approach as potential PSMA bispecific challengers advance.

Angus Liu Apr 28, 2026 10:10am

European Medicines Agency

With EU backing, Sanofi gains long-awaited win for tolebrutinib

Apr 24, 2026 11:30am

NVS

Novartis pledges nearly $480M to bolster China production, R&D

Mar 23, 2026 10:35am

NVS

Novartis details plan for 2nd new US radiopharma plant

Feb 25, 2026 9:55am

Narasimhan

Novartis CEO eyes 2026 growth despite record patent cliff

Feb 4, 2026 2:30pm

Florida Florida flag FL FL flag

Novartis charts next US investment with new radiopharma plant

Jan 9, 2026 10:30am